You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

143 Results
Drug
Other Name(s): Polivy™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2026
Guidelines and Advice
Status: Current
ID: GL 4-11
Version: 2
Updated
Mar 2026
Drug
Other Name(s): Velcade®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Drug
Other Name(s): Treanda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Drug
Other Name(s): Lenvima®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
lenvatinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Regimen
Cancer Type:
Hematologic, 
Myelofibrosis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    momelotinib - For the treatment of splenomegaly and/or disease-related symptoms of myelofibrosis, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
momelotinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
enfortumab vedotin (Unfunded),
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026

Pages